Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213)

Chemical Research in Toxicology

Volumn 26, Issue 3, 2013, Pages 379-387

  Sinha, Birandra K ^a   Bhattacharjee, Suchandra ^a   Chatterjee, Saurabh ^a,c   Jiang, Jinjie ^a   Motten, Ann G ^a   Kumar, Ashutosh ^a   Espey, Michael Graham ^b   Mason, Ronald P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; COMPUTER SIMULATION; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA SUPERCOILING; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MACROPHAGE; MOUSE; NONHUMAN; SPECTROSCOPY; ULTRAVIOLET SPECTROPHOTOMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG RESISTANCE, NEOPLASM; ELECTRON SPIN RESONANCE SPECTROSCOPY; ETOPOSIDE; HL-60 CELLS; HUMANS; MICE; NEOPLASMS; NITRIC OXIDE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84875183812     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx300480q     Document Type: Article

References (64)

1. Henwood, J. M. and Brogden, J. M. (1990) Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentials in combination therapy of cancer Drugs 39, 438-490
2. Haim, N., Nemec, J., Roman, J., and Sinha, B. K. (1986) Peroxidative free radical formation and o -demethylation of etoposide (VP-16) and teniposide (VM-26) Biophys. Biochem. Res Commun. 135, 215-220
3. Haim, N., Nemec, J., Roman, J., and Sinha, B. K. (1987) Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules Cancer Res. 47, 5835-5840
4. Haim, N., Nemec, J., Roman, J., and Sinha, B. K. (1987) In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins Biochem. Pharmacol. 36, 527-536
5. VanMaanen, J. M. S., deVaries, J., and Pappie, D. 1987, Cytochrome-P-450-mediated O -demethylation- a route in the metabolic-activation of etoposide (VP-16213) Cancer Res. 47, 4658-4662
6. Kalayanaraman, B., Nemec, J., and Sinha, B. K. (1989) Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives: an ESR study Biochemistry 28, 4830-4846
7. Kagan, V. E., Kuzmenk, A. I., and Tyurina, Y. Y. 2001, Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: Role of myeloperoxidase Cancer Res. 61, 7777-7784
8. Sinha, B. K., Polliti, P. M., and Eliot, H. M. 1990, Structure-activity relationship, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogs of etoposide Eur. J. Cancer 26, 590-593
9. Gantchev, T. G. and Hunting, D. J. (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II-DNA cleavable complex Mol. Pharmacol. 53, 422-428
10. Sinha, B. K., Eliot, H. M., and Kalyanaraman, B. (1988) Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16 FEBS Lett. 227, 240-244
11. Sinha, B. K., Antholine, W. M., Kalyanaraman, B., and Eliot, H. M. (1990) Copper ion-dependent oxy-radical-mediated DNA damage from dihydroxy derivative of etoposide Biochim. Biophys. Acta 1096, 81-83
12. Katki, A. G., Kalyanaraman, B., and Sinha, B. K. (1987) Interactions of the antitumor drug, etoposide with reduced thiols in vitro and in vivo Chem-Biol. Interact. 62, 237-247
13. Fan, Y., Schreiber, E. M., and Giorgianni, A. 2006, Myeloperoxidase- catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells Chem. Res. Toxicol. 19, 937-943
14. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors Med. Pediatr. Oncol. 36, 525-535
15. Kagan, V. E., Yalowich, J. C., and Borisenko, G. G. 1999, Mechanism-based chemopreventive strategies against etoposide-induced myeloid leukemia: free radical/antioxidant approach Mol. Pharmacol. 56, 494-506
16. Lovett, B. D., Strumberg, D., and Blair, I. A. 2001, Etoposide metabolite enhances topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints Biochemistry 40, 1159-1170
17. Jenkins, D. C., Charles, I. G., and Thomsen, L. L. 1995, Roles of nitric oxide in tumor growth Proc. Natl. Acad. Sci. U.S.A. 92, 4392-96
18. Thomsen, L. L., Scott, J. M. J., and Topley, P. 1997, Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a selective inhibitor Cancer Res. 57, 3300-3304
19. Wink, D. A., Vodovotz, Y., and Cook, J. A. 1998, Role of nitric oxide chemistry in cancer treatment Biochemistry (Moscow) 63, 802-809
20. Xu, W. M., Liu, L. Z., and Loizidou, M. 2002, The role of nitric oxide in cancer Cell Res. 12, 311-320
21. Chen, G. G., Lee, T. W., and Xu, H. Y. 2008, Increased inducible nitric oxide synthase in lung carcinoma of smokers Cancer 112, 372-381
22. Cook, J. A., Krishna, M. C., and Pacelli, R. 1997, Nitric oxide enhancement of melphalan-induced cytotoxicity Br. J. Cancer 76, 325-334
23. Wink, D. A., Cook, J. A., and Christodoulou, D. 1987, Nitric oxide and some NO donor compounds enhance the cytotoxicity of cisplatin Nitric Oxide 1, 88-94
24. Yang, D-T, Yin, J. H., and Mishra, S. 2002, NO-mediated chemoresistance in C6 glioma cell Ann. N.Y. Acad. Sci. 962, 8-17
25. Wilcox, A. L. and Janzen, E. G. (1993) Nitric oxide reactions with antioxidant in model systems: sterically hindered phenols and alpha tocopherol in sodium dodecyl-sulphate (SDS) micelle J. Chem. Soc. Chem. Commun. 18, 1377-1379
26. Janzen, E. G., Wilcox, A. L., and Manoharan, V. (1993) Reactions of nitric oxides with phenolic antioxidants and phenoxy radicals J. Org. Chem. 58, 3597-3599
27. Cudic, M. and Ducrocq, C. (2000) Transformations of 2,6-diisopropylphenol by NO-derived nitrogen oxides, particularly peroxynitrite Nitric Oxide 4, 147-156
28. Yenes, S. and Messeguer, A. (1999) A study of the reaction of different phenol substrate with nitric oxide and peroxynitrite Tetrahedron 55, 14111-14122
29. Curtis, J. F., Reddy, N. G., and Mason, R. P. 1996, Nitric oxide: A prostaglandin H synthase 1 and 2 reducing co-substrate that does not stimulate cyclooxygenase activity or prostaglandin expression in Maurine macrophages Arch. Biochem. Biophys. 335, 369-376
30. Chatterjee, S., Lardinois, O., and Bonini, M. G. 2009, Site-specific carboxypeptidase B1 tyrosine nitration and pathophysiological implications following its physical association with nitric oxide synthase-3 in experimental sepsis J. Immunol. 183, 4055-4066
31. Sjoberg, B. M., Reichard, P., Graslund, A., and Ehrenberg, A. (1977) Nature of the free radical in ribonucleotide reductase from Escherichia coli J. Biol. Chem. 252, 536-541
32. Lepoivre, M., Flaman, J. M., and Bobe, P. 1994, Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide-relationship to cytostasis induced in tumor-cell by cytotoxic macrophages J. Biol. Chem. 269, 21891-21897
33. Loike, J. D. and Horwitz, S. B. (1976) Effects of VP-16-213 on the intracellular degradation of DNA in HeLa cells Biochemistry 15, 5448-5453
34. Long, B. H., Musial, S. T., and Brattain, M. G. (1984) Comparison of cytotoxicity and DNA breakage of congeners of phodophyllotoxin including VP-16-213 and VM-26: a quantitative structure-activity relationship Biochemistry 23, 1183-1188
35. Nemec, J. (1986) Epipodophyllotoxinquinone Glucoside Derivatives, Method of Production and Use, US Patent 4609644.
36. Duling, D. R. (1994) Simulation of multiple isotropic spin-trap ESR spectra J. Mag. Reson. Ser. B 104, 105-110
37. Barrett, J. F., Gootz, T. D., McGuirk, P. R., and Farrell, C. A. 1989, Use of in vitro topoisomerase-II assay for studying quinolone antibacterial agents Antimicrob. Agents Chemother. 33, 1697-1703
38. Yamazaki, H., Dilworth, A., Myers, C. E., and Sinha, B. K. (1993) Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors Prostate 23, 25-36
39. Kim, H. J., Tsoyi, K., and Heo, J. M. 2007, Regulation of lipopolysaccharide-induced inducible nitric-oxide synthase expression through the nuclear factor kB pathway and interferon-β/tyrosine kinase 2/Janus tyrosine kinase-2 signal transducer and activator of transcription-1 signaling cascades by 2-naphthyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI-53), a new synthetic isoquinoline alkaloid JPET 320, 782-798
40. Lu, S-C, Wu, H-W, and Lin, Y-J 2007, The essential role of Oct-2 in LPS-induced expression of iNOS in Raw 264-7 macrophages and its regulation by trichostatin Am. J. Physol. Cell Physiol. 296, C1133-C1139
41. Espey, M. G., Miranda, K. M., Pluta, R. M., and Wink, D. A. (2000) Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals J. Biol. Chem. 275, 11341-11347
42. Alley, M. C., Scudiero, D. A., and Monks, A. 1988, Feasibility of drug screening with panels of human tumor cell lines using a microculture terazolium assay Cancer Res. 48, 589-601
43. Garvey, E. P., Oplinger, J. A., and Furfine, E. S. 1997, 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo J. Biol. Chem. 272, 4959-4963
44. Liu, L. F., Rowe, T. C., and Yang, L. 1983, Cleavage of DNA by mammalian topoisomerase-II J. Biol. Chem. 258, 15356-15371
45. Gunther, M. R., Sturgeon, B. E., and Mason, R. P. (2002) Nitric oxide trapping of the tyrosyl radical-chemistry and biochemistry Toxicology 177, 1-9
46. Lancaster, J. R. and Xie, K. (2006) Tumors face NO problems? Cancer Res. 66, 6459-6462
47. Ambs, S. and Glynn, S. A. (2011) Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer Cell Cycle 10, 619-624
48. Hickok, J. R. and Thomas, D. D. (2010) Nitric oxide and cancer therapy: the emperor has NO clothes Curr. Pharm. Des. 16, 381-391
49. 2 within hydrophobic interior of biological membranes Proc. Natl. Acad. Sci. U.S.A. 95, 2175-2179
50. Espey, M. G., Miranda, K. M., Thomas, D. D., and Wink, D. A. (2001) Distinction between nitrosating mechanisms within human cells and aqueous solutions J. Biol. Chem. 276, 30085-30091
51. Hogg, N., Singh, R. J., Goss, S. P. A., and Kalyanaraman, B. (1996) The reaction between nitric oxide and a-tocopherol: a reappraisal Biochem. Biophys. Res. Commun. 224, 696-702
52. 2 and peroxynitrite in membranes: Physiological implications Free Radical Res. 31, 597-606
53. Jin, J., Wu, L., and Zhang, Z. (2002) Electron paramagnetic resonance study of nitroxides generated from nitric oxide by reaction with transient radicals Magn. Reson. Chem. 40, 284-288
54. Ross, W. E. (1985) DNA topoisomerases as targets for cancer therapy Biochem. Pharmacol. 34, 4191-4195
55. Glisson, B., Gupta, R., Smallwood-Kentro, S., and Ross, W. E. (1986) Characterization of acquired epipodophyllotoxin resistance in Chinese-Hamster Ovary cell-line: loss of drug-stimulated DNA cleavage activity Cancer Res. 46, 1934-1938
56. Sinha, B. K., Haim, N., and Durse, L. 1988, DNA strand breaks produced by etoposide (VP16-213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action Cancer Res. 48, 5096-6000
57. 2 reactions Chem. Res. Toxicol. 20, 709-714
58. Zhuang, L., Lin, J., and Lu, M. L. 2002, Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells Cancer Res. 62, 2227-2231
59. Miersch, S., Espey, M. G., and Chaube, R. 2008, Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling J. Biol. Chem. 283, 18513-18521
60. Lewis, C. E. and Pollard, J. W. (2006) Distinct role of macrophages in different tumor microenvironments Cancer Res. 66, 605-612
61. Pollard, J. W. (2008) macrophages define the invasive microenvironment in breast cancer J. Leukocyte Biol. 84, 623-630
62. Green, C. E., Liu, T., and Montel, V. 2009, Chemoattractant signaliing between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization PLoS One 4, 1-15
63. Glynn, S. A., Boersma, B. J., and Dorsey, T. H. 2010, Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients J. Clin Invest. 210, 3843-3854
64. Grimm, E. A. and Ellerhorst, J. 2008, Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis Nitric Oxide 19, 133-137